Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
results source : Ir.akerotx.com save search
Akero Therapeutics to Present Results from Phase 2b Expansion Cohort of SYMMETRY Trial Evaluating Efruxifermin in Combination with GLP-1
Published: 2023-06-01 (Crawled : 20:00) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: 0.73%
H: 3.37%
C: 2.82%
efruxifermin expansion trial therapeutics results
Akero Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
Published: 2023-03-17 (Crawled : 11:00) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: 0.58%
H: 1.98%
C: 0.65%
year therapeutics financial results
Akero Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
Published: 2022-11-04 (Crawled : 11:00) - ir.akerotx.com
MS | News 0 d | $90.08 1.06% -0.28% 9.5M
|
Finance
|
| O: 1.83%
H: 0.7%
C: -0.35%
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: -0.46%
H: 4.12%
C: -5.62%
therapeutics financial update results
Akero Therapeutics to Present Results from Phase 2b HARMONY Trial Investigating Efruxifermin in Patients with Pre-Cirrhotic NASH
Published: 2022-09-08 (Crawled : 20:00) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: -1.37%
H: 0.08%
C: -9.92%
trial therapeutics results nash efruxifermin phase 2b
Akero Therapeutics Reports Second Quarter 2022 Financial Results and Provides Business Update
Published: 2022-08-04 (Crawled : 21:00) - ir.akerotx.com
PFE A | $25.42 -1.05% -0.04% 44M
|
Health Technology
|
| O: -0.44%
H: 0.66%
C: -0.75%
HTGC F | $18.16 0.95% -0.22% 730K
|
Finance
|
| O: 0.13%
H: 2.69%
C: 2.69%
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: 1.33%
H: 6.94%
C: 6.33%
therapeutics update results
Akero Therapeutics Reports First Quarter 2022 Financial Results
Published: 2022-05-06 (Crawled : 16:20) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: -4.21%
H: 0.0%
C: 0.0%
therapeutics results
Akero Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Update
Published: 2021-11-12 (Crawled : 00:20) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: 0.69%
H: 0.0%
C: 0.0%
financial results results
Akero Therapeutics to Present Efruxifermin (EFX) Results Showing Histologic Improvement in EFX-Treated F4 Cirrhotic Patients as a Late-Breaker Oral Presentation at the 2021 International Liver Congress
Published: 2021-06-01 (Crawled : 12:00) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: -1.72%
H: 3.93%
C: 2.29%
presentation results liver efruxifermin
Akero Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
Published: 2021-05-13 (Crawled : 11:00) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: 0.04%
H: 2.33%
C: 0.8%
financial results results
Akero Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results
Published: 2021-03-16 (Crawled : 12:00) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: -0.91%
H: 0.0%
C: -2.85%
financial results results
Akero Therapeutics Reports Third Quarter 2020 Financial Results
Published: 2020-11-12 (Crawled : 15:25) - ir.akerotx.com
AKRO | $21.62 -0.78% -0.79% 820K
|
Health Technology
|
| O: 6.86%
H: 0.0%
C: -9.97%
financial results results therapeutics
Gainers vs Losers
| 56% | 44% |
Top 10 Gainers
INVO | $1.76 131.58% 56.82% 230M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.73 47.91% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 640K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.38 30.58% 23.42% 300K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.